Dr. Johnson is an internationally recognized orthopedic surgeon. As such he is an inventor and holder of more than 75 US patents in medicine and surgery. He was one of the pioneers in arthroscopic surgery and the inventor of the motorized instrumentation still used world-wide today in all such surgical procedures. He invented the first non-reactive bioabsorbable implants for orthopedic surgery. He founded a surgical specialty company, Instrument Makar, Inc. This was sold to Smith+Nephew in 2002. He is the founder of the parent company of A-Cosmetic; Anti-Oxidant USA Research and Development. We at AntiOxidant USA Research and Development (AOUSA R&D) are committed to well being. Our founder Dr. Johnson continues to make a difference in health care. In 2018 he was invited to submit the following manuscript to the Bone and Joint Journal that reflected upon his career; a short autobiographical article.
In 2018 he was invited to submit the following manuscript to the Bone and Joint Journal that reflected upon his career; a short autobiographical article.
Johnson LL. What’s Important: Making a Difference May Include Being Different. J Bone Joint Surg. 2018 Mar 7; 100 (5): 443. DOI 10.2106/JBJS.18.00011.
After concluding his clinical practice, he has continued his interest in medical research and development. In 2005, upon learning that the dyes found in cherries would stimulate rodent pancreatic cells to produce insulin, he reasoned there may be other applications. Independent studies at Scripps Institute in La Jolla, California confirmed his hypothesis that these dyes would cause the human joint lining to turn on the growth hormone gene for Insulin Like Growth Factor-1. IGF-1 has long been known to heal articular cartilage. This resulted in US patents for intra articular injection treatment of degenerative arthritis; i.e. knee, hip, shoulder, etc. The patents were a follows:
8, 263,069 Compositions including anthocyanin or anthocyanidins for the prevention or treatment of articular cartilage-associated conditions. September 11, 2012.
9,486,468: Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions. November 8, 2016
While waiting for these patents to be issued, he learned from the medical literature that various plant extracts having these dyes, anthocyanins and anthocyanidins had antibacterial properties. He commissioned independent in vitro laboratory studies that showed the parent dyes were weak antibiotics. However, the primary metabolites; protocatechuic acid (PCA) and 2,4,6 tri-hydroxybenzaldehyde (246THBA) were very powerful broad-spectrum antibiotics. The subsequent metabolites, vanillic and hippuric acid had few antibiotic properties.
As a result of these studies he was granted a US patent on these primary metabolites for their antibiotic and wound healing properties.
9,498,413: B2 Antimicrobials and methods of use thereof for wound healing. November 22, 2016.
Collagen production and scar reduction: These studies on wound healing also demonstrated that PCA would produce more collagen in the skin following tape stripping of the rodent skin. This study method replicated the clinical procedures of exfoliation or dermabrasion. US patent claims have been granted for this application as USA patent No. 9,925,152 that was issued on March 27, 2018.
Control Human Skin Acne: Subsequently, he funded a two-year, four phase human proof of principle study in attempt to sanitize the skin in human volunteers at Loma Linda Medical School. This was performed on medical student volunteers. He was seeking a means of disinfecting the human skin prior to surgery since the bacteria of the skin are one source of surgical infections. Attention was given especially to Propionibacterium acnes which in recent years as emerged as the bacteria uniquely causing shoulder and spine surgery infections. One result from these studies was the discovery of an antioxidant formulation that would control the various potential pathogens on normal skin while preserving the commensal normal bacteria.
He also commissioned studies at WuXiapptec of Marietta GA from which he learned that PCA in certain concentrations would destroy the biofilm covered colonies of serious pathogens; Methicillin Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. This led to US patents granted concerning the coating of medical and surgical implants to prevent wound infections following total knee and total hip surgery.
He has an application underway with the Environmental Protection Agency concerning a spray for hard surfaces that will be helpful in hospitals and clinics to sanitize these environments of pathological microbes.
He envisions PCA as being the basis for a new industry, addressing multiple health, humanitarian and societal problems.
He launched OAUSA R&D in 2018 to meet those needs.